To assist in selecting the optimal vector system for use in the CHAVI clinical studies, a comparison was done in rhesus monkeys between VSV and Ad to assess the magnitude and durability of vaccine-elicited T lymphocyte immune responses. The VSV vectors used in this study were made with N4CT9, a pathologically attenuated strain of the vims developed by Wyeth. The immunogenicity of these vectors was compared with that of an Eldeleted, E3-inactivated Ad5 developed by Gary Nabel, VRC and GenVec. Both vectors carried an identical HIV-1 HXBc2 gag gene insert. Ad5-seronegative monkeys were immunized at 0 and 8 weeks. Six monkeys received intramuscular inoculations of 108 pfu rVSV Indiana followed by the same dose of rVSV New Jersey, a vector that is not cross-neutralized by antibodies generated by rVSV Indiana. Six monkeys received the same immunogens delivered by the intratracheal route. Another 6 monkeys received 1011 rAd5 followed by the same dose of the same recombinant vector. Cellular immune responses were monitored by pooled peptide Elispot and ICS assays. As shown below, significant Gag-specific immune responses were only detected in the rVSVimmunized monkeys following the boosting immunization. Moreover, the immune responses elicited by the rVSV following the boosting immunization were comparable in magnitude following intratracheal and intramuscular administration, and reached the same magnitude seen following a single immunization with the rAd5 vector.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI067854-07
Application #
8294667
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2011-07-01
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2013-06-30
Support Year
7
Fiscal Year
2011
Total Cost
$1,645,792
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Song, Hongshuo; Giorgi, Elena E; Ganusov, Vitaly V et al. (2018) Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nat Commun 9:1928
Boelen, Lies; Debebe, Bisrat; Silveira, Marcos et al. (2018) Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1. Sci Immunol 3:
Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146
Gelfman, Sahar; Wang, Quanli; McSweeney, K Melodi et al. (2017) Annotating pathogenic non-coding variants in genic regions. Nat Commun 8:236
Mori, Mari; Haskell, Gloria; Kazi, Zoheb et al. (2017) Sensitivity of whole exome sequencing in detecting infantile- and late-onset Pompe disease. Mol Genet Metab 122:189-197
Seaton, Kelly E; Vandergrift, Nathan A; Deal, Aaron W et al. (2017) Computational analysis of antibody dynamics identifies recent HIV-1 infection. JCI Insight 2:
Go, Eden P; Ding, Haitao; Zhang, Shijian et al. (2017) Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. J Virol 91:
Roohi, Jasmin; Crowe, Jennifer; Loredan, Denis et al. (2017) New diagnosis of atypical ataxia-telangiectasia in a 17-year-old boy with T-cell acute lymphoblastic leukemia and a novel ATM mutation. J Hum Genet 62:581-584
Epi4K Consortium; EuroEPINOMICS-RES Consortium; Epilepsy Phenome Genome Project (2017) Application of rare variant transmission disequilibrium tests to epileptic encephalopathy trio sequence data. Eur J Hum Genet 25:894-899
Liu, Donglai; Wang, Chu; Hora, Bhavna et al. (2017) A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology 14:46

Showing the most recent 10 out of 395 publications